Vertex Pharmaceuticals Third Quarter 2026 Earnings Call - CRINETICS PHARMACEUTICALS INC

Financial Performance:

• Total revenue grew 12% year-over-year (YoY) to an estimated ~$3.4 billion for Q3 2026, with 10% growth in the U.S. and 16% internationally.
• Revenue drivers included CF (8% YoY growth), Heme (30% sequential growth for Casgevi), Pain (18% QoQ growth for Jernavix), and Rare Endocrinology ($24M contribution from Palsonify post-acquisition).
• Non-GAAP gross margin was 85.6%; GAAP gross margin was 84.7% due to amortization from the Krenetics acquisition.
• Non-GAAP net income was $1.21 billion, with EPS of $4.76; effective tax rate was 18%.
• Cash and investments ended the quarter at $9.8 billion; $4.5 billion in term loans were raised at ~4.8% interest to fund the Krenetics deal.
• Operating expenses increased 51% YoY to $556M (SG&A) and 9% YoY to $936M (R&D) to support commercial infrastructure and Krenetics integration ($60M incurred in Q3).

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $13.15–$13.25 billion (previously $13.1–$13.2 billion) to reflect Krenetics contribution ($40–$50M expected).
• Projected full-year non-GAAP operating expenses at ~$6.0 billion (up from $5.65–$5.75 billion) to include ~$250M in Krenetics integration and operating costs.
• Full-year gross margins expected slightly below 86%; non-GAAP tax rate anticipated between 19.5% and 20.5%.
• Long-term goal to exceed $500M in non-CF revenue (driven by Casgevi, Jernavix, and Palsonify) by year-end.
• POVI launch readiness confirmed for PDUFA date (Nov 30), with global expansion ambitions including accelerated approval filings in Saudi Arabia.

Business Segments and Product Lines:

• Cystic Fibrosis (CF): Olifrec revenue reached $3.3B globally; >$1B YTD in the U.S. Submissions initiated for approval in children ages 2–5; next-gen 3.0 corrector (VX828) showed promise in FMF mutations but will be held pending comparative data from VX581/VX272.
• Heme (Sickle Cell/Thalassemia): Casgevi revenue was $99M in Q3 with >750 patient initiations since launch; expanding approval to ages 2–11 in U.S., UAE, Bahrain, and 5–11 in UK.
• Pain: Jernavix generated $58M in Q3 (750K+ prescriptions); established as #1 branded oral analgesic in U.S.; Phase III trials for painful diabetic peripheral neuropathy (DPN) on track for mid-2027 results.
• Rare Endocrinology: Palsonify (acquired via Krenetics) reached >40% brand share in initiation/switch; U.S. launch proceeding with 80% reimbursement coverage; Phase III trials underway for congenital adrenal hyperplasia (Atumelanant).
• Renal: PDUFA decision pending for POVI in IgA Nephropathy (IGAN); Amplified Phase 2-3 study for Anaxiplin (AMKD) fully enrolled with interim analysis expected early 2027.

Market and Competitive Landscape:

• POVI positioned against B-cell modulating therapies with a "trifecta" of efficacy, safety, and patient-centric subcutaneous auto-injection (0.46ml, q4w).
• Jernavix challenging decades of opioid prescribing habits; real-world data shows >80% freedom from opioids post-total knee replacement.
• CF market continues to see switching from Trikafta to Olifrec; Olifrec achieves sweat chloride levels near normal carrier ranges.
• Renal market shows high physician enthusiasm for next-gen therapies; POVI aims to capture opportunity in 163K untreated IGAN patients.

Risks and Challenges:

• Regulatory: Citizen petition filed regarding POVI monitoring rules (IgG levels); Vertex maintains confidence in PDUFA outcome and safety profile (0.5% infection rate in trials).
• Financial/Integration: Krenetics acquisition integration costs and financing expenses ($50M+ non-operating costs in Q3) impacted current margins and cash balances.
• Commercial: Jernavix gross-to-net ratios temporarily depressed by patient support programs (PSP) and one-time Medicare Part D access shifts; PSP expected to sunset mid-2027.
• Clinical: Next-gen 3.0 CF corrector data must be compared across the family (VX828, VX581, VX272) to select the lead candidate for pivotal trials.

Management Commentary and Tone:

• Tone was highly confident, emphasizing "excellent commercial results," "pipeline advancement," and successful integration of Krenetics.
• CEO Reshma Kewalramani praised outgoing CFO Charlie Wagner and introduced incoming CFO Jonathan Poole.
• Management highlighted the strategic shift from a CF-only company to a diversified biotech with five commercial pillars.
• Confidence expressed in the "next-gen" pipeline, citing strong safety and tolerability profiles across programs.

Analyst Questions and Answers:

• POVI Monitoring: Responded to citizen petition by noting no opportunistic infections in trials and that IgG excursions are rare; confident in label and FDA engagement.
• Amplitude (Anaxiplin): Defined a "win" as statistically significant GFR improvement (agreed endpoint for accelerated approval); noted proteinuria reduction is consistent with Phase 2.
• Jernavix PSP: Confirmed PSP remains active through 2026 to ensure access, with gross-to-net normalization expected mid-2027.
• CF Next-Gen: Explained delay in advancing VX828 to allow comparison with other NG3.0 molecules (VX581, VX272) to identify the optimal lead.
• Manufacturing: Confirmed FDA involvement in POVI manufacturing (including continuous manufacturing) and comfort with the CMC package.

Other Key Points:

• Transition of CFO leadership: Charlie Wagner moving to COO (last call as CFO); Jonathan Poole taking over as CFO on Jan 1, 2027.
• Krenetics acquisition closed in September, adding Palsonify (Acromegaly) as the 8th commercialized medicine.
• T1D program prioritized VX017 (allogeneic, glucose-responsive cell therapy) to address manufacturing complexity and expand eligible patient pool to 120K.
• Myotonic Dystrophy (Galileo trial) and Generalized Myasthenia Gravis (Aetna study) on track for data readouts in 2027.
• Global regulatory ambition for POVI includes seeking two-year GFR data for full commercialization outside the U.S.